Selective Serotonin Reuptake Inhibitors, commonly known as SSRIs, are a class of widely prescribed antidepressant medications. They play a vital role in the management of various mental health conditions, particularly depression and anxiety disorders. SSRIs work by targeting serotonin, a neurotransmitter that regulates mood, emotions, and several physiological functions, making them essential tools in the field of psychopharmacology.
SSRIs act on the serotonin transporter (SERT) molecules, which are responsible for reabsorbing serotonin into nerve cells after its release. The primary mechanism of SSRIs involves blocking the reuptake of serotonin by inhibiting SERT. By doing so, SSRIs increase the concentration of serotonin in the synaptic cleft, leading to enhanced neurotransmission and improved mood regulation. SSRIs primarily treat depression and various anxiety disorders, including generalized anxiety disorder, social anxiety disorder, and panic disorder. Additionally, they are prescribed for obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and certain eating disorders. According to the World Health Organization (WHO), depression is a major global health concern, affecting more than 264 million people worldwide, making SSRIs a crucial intervention in addressing this prevalent mental health condition. Extensive research is being conducted globally to discover new and novel molecules to be used, like vilazodone, that is used for the treatment of many indications like Major Depressive Disorder (MDD). The development and launch of new products will thus increase the market's revenue in the forecasted years.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. 7 companies have various products in their pipelines, with 17 products in different stages of clinical trials – 1 in Phase 4, 1 in Phase 3, and 4 in Phase 2 of the clinical trials.
Approved Serotonin Uptake Inhibitor molecules
- Viibryd (vilazodone)
Drugs in the Pipeline of Selective Serotonin Reuptake Inhibitors
- Ammoxetine Hydrochloride
- Mitizodone Phosphate (Hec113995 Pa)
- Aripiprazole/Sertraline (Asc-01)
- Hypidone Hydrochloride (Hht101)
- Gabapentin/Trazodone
Clinical Activity and Developments of Selective Serotonin Reuptake Inhibitors
As of July 2023, 7 companies have approximately 17 products for 240 diseases. For these diseases, 219 trials are being conducted by players globally. For instance,
- Sunshine Lake Pharma Co., Ltd. is conducting a Phase 2/3 clinical trial to evaluate the efficacy and safety of Mitizodone Phosphate Tablets in the treatment of patients with Major Depressive Disorder that is expected to complete by May 2024.
- S. Army Medical Research and Development Command is conducting a Phase 2 clinical trial to evaluate the safety, tolerability, and efficacy of potential pharmacotherapeutic interventions in active-duty service members and veterans with PTSD that is estimated to be complete by September 2026.
|
Molecule name |
Number of studies |
|
Viibryd (vilazodone) |
29 |
|
ammoxetine hydrochloride |
4 |
|
mitizodone phosphate (HEC113995 PA) |
4 |
|
aripiprazole/sertraline (ASC-01) |
3 |
|
hypidone hydrochloride (HHT101)
|
3 |
Target Indication Analysis of Selective Serotonin Reuptake Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs) have a diverse range of indications in the field of psychiatry and mental health. Among the various applications, SSRIs find the most significant use in treating major depressive disorder (MDD), where they serve as a first-line therapy due to their effectiveness in alleviating depressive symptoms and improving overall mood. Additionally, SSRIs are widely prescribed for generalized anxiety disorder (GAD) and social anxiety disorder (SAD), relieving excessive worry and anxiety in these conditions. They also play a crucial role in managing panic disorder, effectively reducing the frequency and intensity of panic attacks. Furthermore, SSRIs are used in treating obsessive-compulsive disorder (OCD), helping to alleviate distressing and intrusive thoughts, and post-traumatic stress disorder (PTSD), assisting in managing traumatic stress-related symptoms. Their versatility extends to conditions like bulimia nervosa and premenstrual dysphoric disorder (PMDD), further showcasing their importance as essential tools in modern psychiatric care.
Selective Serotonin Reuptake Inhibitors Regional Analysis
Selective Serotonin Reuptake Inhibitors Market
Depressive disorder or Depression is the most common mental disorder globally, with an estimated 5% of adults suffering from it, according to the WHO report. Depression affects women more than men. An estimated 8% global population, near to 280 million people, experiences depression, including 5% of adults and 5.7% of adults older than 60 years of age. According to a research study of 2020 in the USA, around 21 million (8.5%) adults had at least 1 major depressive episode, with the prevalence highest amongst the age group of 18-25 years (17%). According to the Anxiety and Depression Association of America, in 2022, 3.1% or 6.8 million people in the USA will be affected by Generalized Anxiety Disorder (GAD), yet only 43.2% receive treatment. Thus, there is an opportunity for the market players globally to launch their products and expand their market.
Latin America
Europe
Asia Pacific
Middle East
North America
LOCATION
Geography
Frequently Asked Questions
Viibryd (vilazodone) has been approved by the FDA as a Serotonin Uptake Inhibitor.
These are used for the treatment of various disorders like Major Depressive Disorders (MDD), Generalized Anxiety Disorder (GAD), obsessive-compulsive disorder (OCD), and others.
AbbVie, CSPC Pharma, HEC Pharma Co., Ltd, and Otsuka Pharmaceutical are some major market players for Selective Serotonin Reuptake Inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and rising incidence of various types of disorders like MDD, OCD, GAD, and others are the key opportunities for Selective Serotonin Reuptake Inhibitors in the market.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- AbbVie
- CSPC Pharma
- HEC Pharma Co., Ltd
- Otsuka Pharmaceutical
- Zhejiang Huahai Pharmaceutical
- Angelini Pharma